Survey of Ophthalmology
Volume 42, Issue 4 , Pages 367-372 , January 1998

Potential Neuroprotective Therapy for Glaucomatous Optic Neuropathy

  • Eti Yoles, PhD

      Affiliations

    • Department of Neurobiology, The Weizmann Institute of Science, Rehovot, Israel
    • ,
  • Michal Schwartz, PhD

      Affiliations

    • Department of Neurobiology, The Weizmann Institute of Science, Rehovot, Israel

References 

  1. Armaly MF, Krueger DE, Maunder L, et al.  Biostatistical analysis of the collaborative glaucoma study. I. Summary report of the risk factors for glaucomatous visual-field defect. Arch Ophthalmol. 1980;98:2163–2171
  2. Assia E, Rosner M, Belkin M, Schwartz M. Temporal parameters and low-energy laser irradiation for optimal delay of posttraumatic degeneration of rat optic nerve. Brain Res. 1989;476:205–212
  3. Brubaker RF. Delayed functional loss in glaucoma. LII Edward Jackson Memorial Lecture. Am J Ophthalmol. 1996;121:473–483
  4. Bullock R. Strategies for neuroprotection with glutamate antagonists. Ann NY Acad Sci. 1995;765:272–278
  5. Caprioli J. Correlation of visual function with optic nerve and nerve fiber layer structure in glaucoma. Surv Ophthalmol. 1989;33(Suppl):319–330
  6. Choi DA. Glutamate neurotoxicity and diseases of the nervous system. Neuron. 1988;1:623–634
  7. Choi DW. The role of glutamate neurotoxicity in hypoxic-ischemic neuronal death. Annu Rev Neurosci. 1990;13:171–182
  8. Crowe MJ, Bresnahan JC, Shuman SL, et al.  Apoptosis and delayed degeneration after spinal cord injury in rats and monkeys. Nat Med. 1997;3:73–76
  9. Danysz W, Parsons CG, Bresnick I, Quack G. Glutamate in CNS disorders. Drug News Perspectives. 1995;8:261–277
  10. Doble A. Excitatory amino acid receptors and neurodegeneration. Therapie. 1995;50:319–337
  11. Dreyer EB, Zurakowski D, Schumer RA, et al.  Elevated glutamate levels in the vitrebody of humans and monkeys with glaucoma. Arch Ophthalmol. 1996;114:299–305
  12. Duvdevani R, Rosner M, Belkin M, et al.  Graded crush of the rat optic nerve as a brain injury model (combining electrophysiological and behavioral outcome). Restor Neurol Neurosci. 1990;2:31–38
  13. Eitan S, Solomon A, Lavie V, et al.  Recovery of visual response of injured adult rat optic nerves treated with transglutaminase. Science. 1994;264:1764–1768
  14. Faden AI. Pharmacotherapy in spinal cord injury (a critical review of recent developments). Clin Neuropharmacol. 1987;10:193–204
  15. Faden AI, Salzman S. Pharmacological strategies in CNS trauma. Trends Pharmacol Sci. 1992;13:29–35
  16. Fechtner RD, Weinreb RN. Mechanisms of optic nerve damage in primary open angle glaucoma. Surv Ophthalmol. 1994;39:23–42
  17. Garcia-Valenzuela E, Shareef S, Walsh J, Sharma SC. Programmed cell death of retinal ganglion cells during experimental glaucoma. Exp Eye Res. 1995;61:33–44
  18. Jones KA, Baughman RW. Both NMDA and non-NMDA subtypes of glutamate receptors are concentrated at synapses on cerebral cortical neurons in culture. Neuron. 1991;7:593–603
  19. Kitazawa Y, Horie T, Aoki S, et al.  Untreated ocular hypertension. Arch Ophthalmol. 1977;95:1180–1184
  20. Leske MC. The epidemiology of open-angle glaucoma (a review). Am J Epidemiol. 1983;118:166–191
  21. Liu D, Yang R, Yan X, McAdoo DJ. Hydroxyl radicals generated in vivo kill neurons in the rat spinal cord (Electrophysiological, histological, and neurochemical results). J Neurochem. 1994;62:37–44
  22. Lynch DR, Dawson TM. Secondary mechanisms in neuronal trauma. Curr Opin Neurol. 1994;7:510–516
  23. McIntosh TK. Novel pharmacologic therapies in the treatment of experimental traumatic brain injury (A review). J Neurotrauma. 1993;10:15–61
  24. Muir KW, Lees KR. Clinical experience with excitatory amino acid antagonist drugs. Stroke. 1995;26:503–513
  25. Perkins ES. The Bedford glaucoma survey. I. Long-term follow-up of borderline cases. Br J Ophthalmol. 1975;57:179–185
  26. Povlishock JT, Christman CW. The pathobiology of traumatically induced axonal injury in animals and humans (A review of current thoughts). J Neurotrauma. 1995;12:555–564
  27. Quigley HA, Addicks EM, Green WR, Maumenee AE. Optic nerve damage in human glaucoma. II. The site of injury and susceptibility to damage. Am J Ophthalmol. 1981;99:635–649
  28. Quigley HA, Nickells RW, Kerrigan LA, et al.  Retinal ganglion cell death in experimental glaucoma and after axotomy occurs by apoptosis. Invest Ophthalmol Vis Sci. 1995;36:774–786
  29. Ransom BR, Waxman SG, Davis PK. Anoxic injury of CNS white matter (Protective effect of ketamine). Neurology. 1990;40:1399–1403
  30. Schumer RA, Podos SM. The nerve of glaucoma!. Arch Ophthalmol. 1994;112:37–44
  31. Shohami E, Novikov M, Mechoulam R. A nonpsychotropic cannabinoid, HU-211, has cerebroprotective effect after closed head injury in the rat. J Neurotrauma. 1993;10:109–119
  32. Siesjo BK. Mechanisms of ischemic brain damage. Crit Care Med. 1988;16:954–963
  33. Sommer A, Katz J, Quigley HA, et al.  Clinically detectable nerve fiber atrophy precedes the onset of glaucomatous field loss. Arch Ophthalmol. 1991;109:77–83
  34. Sommer A, Tielsch JM, Katz J, et al.  Relationship between intraocular pressure and primary open-angle glaucoma among white and black Americans. Arch Ophthalmol. 1991;109:1090–1095
  35. Stys PK, Ransom BR, Waxman SG. Compound action potential of nerve recorded by suction electrode (a theoretical and experimental analysis). Brain Res. 1991;546:18–32
  36. Villegas-Prez MP, Vidal-Sanz M, Rasmunsky M, et al.  Rapid and protracted phases of retinal ganglion cell loss follows axotomy in the optic nerve of adult rat. J Neurobiol. 1993;24:23–36
  37. Yoles E, Belkin M, Schwartz M. HU-211, a nonpsychotropic cannabinoid, produces a short- and long-term neuroprotection after optic nerve axotomy. J Neurotrauma. 1996;13:49–57
  38. Yoles E, Muller S, Schwartz M: NMDA-receptor antagonist acts as a survival factor in partially lesioned optic nerve: Implications for glaucoma therapy (submitted).
  39. Yoles E, Zalish M, Lavie V, et al.  GM1 reduces early injury-induced metabolic deficits and subsequent degeneration in the rat optic nerve. Invest Ophthalmol Vis Sci. 1992;83:3586–3591

PII: S0039-6257(97)00123-9

doi: 10.1016/S0039-6257(97)00123-9

Survey of Ophthalmology
Volume 42, Issue 4 , Pages 367-372 , January 1998

Article Tools

* Image Usage & Resolution